Highlights bei Lungenkrebs

Im Video besprochene Studien

DeLLphi-305

Tarlatamab + Durvalumab als Erhaltung beim ES-SCLC
Pérol M et al. Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. N Engl J Med, online 24.10.2026. DOI: 10.1056/NEJMoa2609482. ESMO 2026: LBA3.

Moser D et al. Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry. Lung Cancer 2026;221:109639. DOI: 10.1016/j.lungcan.2026.109639.

Krascendo 1

Divarasib vs. Sotorasib/Adagrasib bei vorbehandeltem KRAS-G12C-mutiertem NSCLC
Skoulidis F et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC. N Engl J Med, online 25.10.2026. DOI: 10.1056/NEJMoa2605703. ESMO 2026: LBA5.

SAFFRON

Osimertinib + Savolitinib nach Osimertinib-Progression bei MET-Überexpression und/oder -Amplifikation
Lu S et al. Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. N Engl J Med, online 25.10.2026. DOI: 10.1056/NEJMoa2611335. ESMO 2026: LBA6.

COCOON

Subkutanes Amivantamab + Lazertinib, dermatologische Prophylaxe und Lazertinib-Vorlauf
Cho BC, Tan JL, Li W et al. Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line subcutaneous amivantamab + lazertinib: first results from new COCOON cohorts. ESMO 2026: 2700RO, aktualisierte orale Präsentation.

OptiTROP-Lung04

Sacituzumab Tirumotecan nach EGFR-TKI; finales OS-Update
Fang W et al. Final OS analysis of sacituzumab tirumotecan versus platinum-based chemotherapy in EGFR-mutated NSCLC after progression on EGFR-TKI: phase III OptiTROP-Lung04 study. ESMO 2026: LBA67. Frühere Vollpublikation zur PFS- und OS-Interimsanalyse: Fang W et al. Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med 2026;394:13–26. DOI: 10.1056/NEJMoa2512071.

PERSEE / GFPC 01-2020

Pembrolizumab ± Chemotherapie bei NSCLC mit PD-L1 ≥50 %
Descourt R et al. Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). Ann Oncol, online 25.10.2026. DOI: 10.1016/j.annonc.2026.10.108. ESMO 2026: 2614O.

OptiTROP-Lung06

Sacituzumab Tirumotecan + Pembrolizumab bei PD-L1-negativem nichtplattenepithelialem NSCLC
Zhou F et al. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC. N Engl J Med, online 25.10.2026. DOI: 10.1056/NEJMoa2611280. ESMO 2026: LBA66.

MOIO

Verlängerte ICI-Gabeintervalle nach Ansprechen auf sechs Monate Immuntherapie
Gravis G et al. MOIO: Interim analyses of a phase III randomized non inferiority trial assessing reduced frequency immune checkpoint inhibitors in responding patients with advanced/metastatic cancer. ESMO 2026: LBA10.